Off-label drug use in breast cancer therapy
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have undergone randomized clinical studies and have been registered for that specific indication. However, a number of drugs are used in an off-label manner, i.e. outside the officially approved product specifications. The paper discusses the use of several off-label therapies in breast cancer in order to demonstrate that such treatment may be well-grounded and indeed turns out beneficial in many cases. It describes the use of liposomal doxorubicin in pre- and post-operative treatment, capecitabine for incomplete efficacy of preoperative treatment, and the administration of metronomic vinorelbine. Moreover, the paper is aimed at demonstrating the legal basis and the principles of marketing authorization of off-label drug use.
Authors and Affiliations
Tomasz Jankowski, Monika Urbaniak
Keywords
Related Articles
- EP ID EP189723
- DOI 10.24292/01.OR.300617.5
- Views 248
- Downloads 0
Why does reimbursement of orphan drugs require a specific approach?
The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of...
ICOS Annual Conference Meeting in Washington DC - importance for scientific activity in Eastern Europe
Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered...
Mięsakorak trzonu macicy jako trzeci nowotwór pacjentki - opis przypadku i omówienie aktualnych zaleceń postępowania
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable...